IFNG and neoplasm: Third, the emergence of HLA-I negative tumor variants by B2M mutations and defects in genes that regulate the IFN-gamma signaling, occurs during the natural history of cancer [26, 35] or after immunotherapy as a result of immune selection [19, 36, 37].